Technical Analysis for CELC - Celcuity Inc.

Grade Last Price % Change Price Change
C 17.83 0.45% 0.08
CELC closed up 0.45 percent on Monday, March 18, 2024, on 1.35 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Mar 21
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Doji - Bullish? Reversal 0.45%
Outside Day Range Expansion 0.45%
Wide Bands Range Expansion 0.45%
Wide Bands Range Expansion 0.11%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 10 hours ago
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
60 Minute Opening Range Breakout about 13 hours ago
2x Volume Pace about 15 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Celcuity Inc. Description

Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Stem Cell Cell Biology Targeted Therapy Signal Transduction Systems Biology Cell Signaling Drug Therapy Patient's Tumor

Is CELC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.95
52 Week Low 8.389
Average Volume 213,490
200-Day Moving Average 12.22
50-Day Moving Average 15.70
20-Day Moving Average 16.88
10-Day Moving Average 18.00
Average True Range 0.81
RSI (14) 60.94
ADX 32.74
+DI 27.02
-DI 15.24
Chandelier Exit (Long, 3 ATRs) 16.53
Chandelier Exit (Short, 3 ATRs) 16.16
Upper Bollinger Bands 19.73
Lower Bollinger Band 14.03
Percent B (%b) 0.67
BandWidth 33.78
MACD Line 0.73
MACD Signal Line 0.74
MACD Histogram -0.0054
Fundamentals Value
Market Cap 449.99 Million
Num Shares 25.2 Million
EPS -2.74
Price-to-Earnings (P/E) Ratio -6.51
Price-to-Sales 0.00
Price-to-Book 4.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.52
Resistance 3 (R3) 18.50 18.25 18.41
Resistance 2 (R2) 18.25 18.07 18.26 18.37
Resistance 1 (R1) 18.04 17.97 17.92 18.06 18.33
Pivot Point 17.79 17.79 17.73 17.80 17.79
Support 1 (S1) 17.58 17.61 17.46 17.60 17.33
Support 2 (S2) 17.33 17.51 17.34 17.29
Support 3 (S3) 17.12 17.33 17.26
Support 4 (S4) 17.14